SEC Form 4 · accession 0000899866-17-000076
ALEXION PHARMACEUTICALS, INC. · ALXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ludwig Hantson
Officer — CEO · Director
Period of report
Mar 29, 2017
Accepted (ET)
Mar 29, 2017 · 6:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000899866
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $.0001 per shareF1 | Mar 29, 2017 | A | 28,725 | $0.00 | A | 57,450 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $118.83 | Mar 29, 2017 | A | 56,762 | A | Mar 27, 2018 | Mar 27, 2027 | Common Stock, par value $.0001 per share | 56,762 | 56,762 | D |
Explanation of responses
- F1Award of Restricted Stock Units under the 2004 Incentive Plan. Vests 25% on each of December 31, 2017, December 31, 2018, March 27, 2020, and March 27, 2021.
- F2Stock option award under 2004 Incentive Plan. Vests 25% on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years.